Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
164 studies found for:    Open Studies | "Blood Platelet Disorders"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Blood Platelet Disorders"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Thrombocytopathy in Gaucher Disease Patients
Conditions: Gaucher Disease;   Thrombocytopathy
Intervention:
2 Recruiting Effects of Exercise Training on Cardiovascular Health in Middle-aged Women
Conditions: Menopause;   Cardiac Function Impaired;   Cardiovascular Diseases;   Blood Platelet Disorders;   Metabolic Diseases
Interventions: Behavioral: Yoga/Pilates;   Behavioral: Spinning
3 Recruiting A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Conditions: Primary Myelofibrosis;   Thrombocythemia, Essential;   Thrombocytosis;   Myeloproliferative Disorders;   Bone Marrow Diseases;   Hematologic Diseases;   Blood Coagulation Disorders;   Blood Platelet Disorders;   Hemorrhagic Disorders
Interventions: Drug: LDE225;   Drug: INC424
4 Not yet recruiting Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder
Condition: Inherited Platelet Disorders
Intervention: Other: Blood collection for platelet protein samples
5 Recruiting Safety and Efficacy of Eltrombopag at Escalated Doses
Conditions: Immune Thrombocytopenia;   Platelet Disorder
Interventions: Drug: Eltrombopag;   Drug: Placebo
6 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
7 Recruiting ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
Condition: Immune Thrombocytopenia
Intervention: Drug: Second Line ITP agents
8 Recruiting Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Interventions: Drug: Anagrelide retard;   Drug: Placebo
9 Not yet recruiting Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Romiplostin
10 Recruiting A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Interventions: Biological: PRM-151;   Drug: Ruxolitinib
11 Unknown  Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: rhIL-11
12 Recruiting Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
Conditions: Hemophilia A;   Hemophilia B;   Von Willebrand's Disease
Intervention:
13 Unknown  Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
14 Recruiting Low-dose Decitabine Versus Recombinant Human Thrombopoietin for the Treatment of Refractory Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Decitabine;   Drug: rhTPO
15 Not yet recruiting Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Conditions: Thrombocytopenia;   Alloimmune Platelet Refractoriness
Intervention: Drug: Eculizumab
16 Recruiting Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis;   Post-Polycythemic Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: NS-018
17 Recruiting Eltrombopag for Post Transplant Thrombocytopenia
Condition: Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Placebo
18 Recruiting Sirolimus for Autoimmune Disease of Blood Cells
Conditions: Autoimmune Pancytopenia;   Autoimmune Lymphoproliferative Syndrome (ALPS);   Evans Syndrome;   Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune;   Autoimmune Neutropenia;   Lupus Erythematosus, Systemic;   Inflammatory Bowel Disease;   Rheumatoid Arthritis
Intervention: Drug: sirolimus
19 Recruiting Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Condition: Idiopathic Thrombocytopenic Purpura
Intervention:
20 Unknown  Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Antox tablets(Mepaco);   Other: drug therapy for ITP

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years